
Seres Therapeutics, Inc.
Seres Therapeutics, Inc.(MCRB)股价预测与分析师目标价
华尔街共识、12 个月目标价、模型推演与 EPS/营收预期 — 来自分析师数据与历史行情。
mcrb · 股价预测 · 18 位分析师(近3月)· FMP · 更新于 2026年6月8日
分析师评级与共识
基于过去 3 个月内 18 位华尔街分析师
Buy
18 位分析师
共识
评级分布
12 个月目标价
High
$1.25
Consensus
$1.25
-80.1% upside
Low
$1.25
Median: $1.25 · Last Close: $6.28
12 个月目标价预测
历史收盘价 + 分析师 12 个月目标价预测区间
短期股价预测
Low Activity算法生成 · 每日更新
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-10 | $5.97 | ↓ 4.91% |
1-day model range: $5.88–$6.06. Peak: $6.06 (-4.91%).
长期股价预测
基于技术分析的股价预测
14 项技术面信号(SMA×6 + EMA×6 + RSI + MACD)· EEAT 方法论透明
Insufficient Trading Activity — Sentiment Signals Disabled
This stock has very low trading volume (ZOMBIE condition). Sentiment analysis requires sufficient price action. RSI and MACD values below are still shown for reference.
Moving Averages · MCRB · Jun 9, 2026
最新分析师评级与调整
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2026-03-13 | Canaccord Genuity | Maintains | Buy→Buy |
| 2025-09-24 | Canaccord Genuity | Maintains | Buy→Buy |
| 2025-05-08 | Chardan Capital | Downgrade ↓ | Buy→Neutral |
| 2025-03-20 | Chardan Capital | Maintains | Buy→Buy |
| 2025-03-14 | Goldman Sachs | Maintains | Sell→Sell |
| 2024-11-14 | Canaccord Genuity | Maintains | Buy→Buy |
| 2024-11-13 | Chardan Capital | Maintains | Buy→Buy |
| 2024-10-24 | JP Morgan | Downgrade ↓ | Neutral→Underweight |
| 2024-09-13 | Canaccord Genuity | Maintains | Buy→Buy |
| 2024-08-14 | Canaccord Genuity | Maintains | Buy→Buy |
Wall Street analysts have recently issued updated ratings on Seres Therapeutics, Inc. (MCRB) stock. Of the recent 62 rating actions, 4 were upgrades and 9 were downgrades. 18 analysts currently cover MCRB.
分析师推荐趋势
MCRB analyst recommendation trends show increasing buy-side sentiment over the past 6 months. Buy rating actions changed from 0 to 1 per month.
财务预测:EPS 与营收一致预期
Revenue This Year
$0M
↓ 62.8% YoY
Revenue Next Year
$1M
↑ 168.5% YoY
EPS This Year
$0.26
EPS Next Year
$-9.19
↓ 3589.9% YoY
EPS ForecastReported vs Estimated
Analysts forecast MCRB EPS of $0.26 for the current fiscal year, based on estimates from 1 analysts. The MCRB revenue forecast is $0M for the current year. These are analyst consensus estimates via FMP / S&P Global.
关于预测与目标价
MCRB 股价预测由两类独立数据源支撑:来自 18 位华尔街分析师(S&P Global / FMP)的共识评级,以及基于历史日终价计算的技术分析。MCRB 的共识目标价为 $1.25(-80.1% 上行空间),分析师共识为 Buy。
MCRB 的短期预测(明日)为 $5.97(-4.91%)。
Seres Therapeutics, Inc. 在 NASDAQ 上市,代码 MCRB。MCRB 在 2027 年的整体展望偏积极,在覆盖分析师中约 61% 对应 Buy 共识。
常见问题
MCRB 预测 · 8 个问题根据 18 位华尔街分析师,MCRB 的 12 个月平均目标价为 $1.25,最高 $1.25、最低 $1.25。若有图表,中位目标价可在上方查看。相对当前价 $6.28,隐含约 -80.1% 的上行空间。
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.